Toxicologic Pathology Forum*: Opinion on Addressing Gaps in INHAND Terminology for Medical Devices—A Proposal to Add New Diagnostic Nomenclature

Historically, safety and efficacy assessment of medical devices began and has continued as standards under the International Organization for Standardization (ISO) rather than under regulatory agency guidelines applied to developing other biomedical product classes. These parallel and unequal pathways have led to multiple and substantive differences in methods and endpoints to determine adverse biological responses among therapeutic classes. Toxicologic pathologists with medical device experience consider standardized nomenclature and diagnostic criteria for medical devices and device-containing combination products as a critical unmet need for nonclinical pathology evaluations. The International Harmonization of Nomenclature and Diagnostic Criteria for Lesions (INHAND) initiative has established globally accepted terminology for proliferative and nonproliferative lesions in various laboratory animal species. Experienced pathologists have identified that some existing INHAND terms for rodents and particularly nonrodents are already used or can be modified for use in medical device studies, but new terms for diagnostic features unique to medical device studies are needed to close gaps in existing INHAND nomenclature. The best approach to establishing appropriate INHAND terms for medical devices (and by extension, device-containing combination products) will be to develop and implement suitable terminology (modified and new, as warranted) to address unmet needs for this distinctive therapeutic class.

Authors

Institutions

Publication Details

Journal
Toxicologic Pathology
Published
2025-04-05
DOI
https://doi.org/10.1177/01926233251331580
Primary Topic
Immunotoxicology and immune responses
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Toxicologic Pathology Forum*: Opinion on Addressing Gaps in INHAND Terminology for Medical Devices—A Proposal to Add New Diagnostic Nomenclature

Lyn M. Wancket, Brad N. Bolon, Kathleen A. Funk, Nicole Kirchhof et al.
Toxicologic Pathology
Immunotoxicology and immune responses
article

Toxicologic Pathology Forum*: Opinion on Addressing Gaps in INHAND Terminology for Medical Devices—A Proposal to Add New Diagnostic Nomenclature

Lyn M. Wancket, Brad N. Bolon, Kathleen A. Funk, Nicole Kirchhof, JoAnn C. L. Schuh, J Rybicka
article en

Abstract

Historically, safety and efficacy assessment of medical devices began and has continued as standards under the International Organization for Standardization (ISO) rather than under regulatory agency guidelines applied to developing other biomedical product classes. These parallel and unequal pathways have led to multiple and substantive differences in methods and endpoints to determine adverse biological responses among therapeutic classes. Toxicologic pathologists with medical device experience consider standardized nomenclature and diagnostic criteria for medical devices and device-containing combination products as a critical unmet need for nonclinical pathology evaluations. The International Harmonization of Nomenclature and Diagnostic Criteria for Lesions (INHAND) initiative has established globally accepted terminology for proliferative and nonproliferative lesions in various laboratory animal species. Experienced pathologists have identified that some existing INHAND terms for rodents and particularly nonrodents are already used or can be modified for use in medical device studies, but new terms for diagnostic features unique to medical device studies are needed to close gaps in existing INHAND nomenclature. The best approach to establishing appropriate INHAND terms for medical devices (and by extension, device-containing combination products) will be to develop and implement suitable terminology (modified and new, as warranted) to address unmet needs for this distinctive therapeutic class.

Toxicologic PathologyVol. 53(5)
Experimental Pathology Laboratories (US), Medtronic (United States) (US), NewPath Research (US), Charles River Laboratories (United States) (US), Virginia Mason Bainbridge Island Medical Center (US)
Partnerships for the goals
Openalex Percentile: Top 92%
Immunotoxicology and immune responses
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.